<DOC>
	<DOCNO>NCT01243398</DOCNO>
	<brief_summary>RATIONALE : Gefitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . It yet know whether gefitinib effective placebo treat esophageal cancer . PURPOSE : This randomized phase III trial study gefitinib see well work compare placebo treat patient esophageal cancer progress chemotherapy .</brief_summary>
	<brief_title>Gefitinib Treating Patients With Esophageal Cancer That Progressing After Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess whether gefitinib v placebo improve overall survival patient esophageal gastroesophageal junction cancer . Secondary - To assess toxicity gefitinib monotherapy patient . - To assess whether gefitinib v placebo significant positive negative impact upon quality life patient . - To assess impact gefitinib v placebo progression-free survival patient . OUTLINE : This multicenter study . - Arm A : Patients receive oral gefitinib daily . Treatment continue absence disease progression unacceptable toxicity . - Arm B : Patients receive oral placebo daily . Treatment continue absence disease progression unacceptable toxicity . Blood sample collect genetic translational study . Patient 's quality life assess baseline periodically study completion EORTC Quality Life Questionnaire ( QLQ-C30 ) version 3.0 . After completion study treatment , patient follow every 8 week .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm esophageal cancer gastroesophageal junction tumor include follow subtypes : Adenocarcinoma Squamous cell cancer Poorly differentiate epithelial malignancy Gastroesophageal junction Siewert type I II tumor Failure 2 prior chemotherapy regimens 1 chemoradiation course Measurable evaluable disease CT scan Patients brain metastasis must stable received cranial irradiation prior entry PATIENT CHARACTERISTICS : WHO performance status 02 Serum bilirubin ≤ 3 time upper limit normal ( ULN ) AST/ALT ≤ 2.5 time ULN ( ≤ 5 x presence liver metastasis ) Able take oral tablet ( whole disperse ) No evidence clinically active interstitial lung disease ( patient chronic , stable , radiographic change asymptomatic allow ) No know severe hypersensitivity gefitinib excipients product No prior malignancy likely confound result interfere gefitinib therapy No medical condition consider interfere safe participation trial Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No chemotherapy ( include oral ) within past 6 week No radiotherapy site measurable evaluable disease within past 4 week No concurrent cytotoxic chemotherapy , immunotherapy , hormonal therapy ( exclude contraceptive replacement steroid ) experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>adenocarcinoma gastroesophageal junction</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage IA esophageal cancer</keyword>
	<keyword>stage IB esophageal cancer</keyword>
	<keyword>stage IIA esophageal cancer</keyword>
	<keyword>stage IIB esophageal cancer</keyword>
	<keyword>stage IIIA esophageal cancer</keyword>
	<keyword>stage IIIB esophageal cancer</keyword>
	<keyword>stage IIIC esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
</DOC>